Elzonris

Active Ingredient(s): Tagraxofusp-erzs
FDA Approved: * December 21, 2018
Pharm Company: * STEMLINE THERAPEEUTICS INC

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Elzonris Overview

Tagraxofusp-erzs (trade name Elzonris) is a drug for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 2018.[1] Tagraxofusp-erzs is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin.[2] The fusion protein readily kills cultured pDC by binding to their IL-3 receptors to thereby gain entrance to the cells and then blocking these cells' protein synthesis (due to its d...

Read more Elzonris Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tagraxofusp-erzs

Recent Elzonris Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Elzonris: (1 result)

Sorted by National Drug Code

• 72187-0401 Elzonris 1000 ug/ml Intravenous Injection, Solution by Stemline Therapeutics, Inc.

Other drugs which contain Tagraxofusp-erzs or a similar ingredient: (1 result)

• TAGRAXOFUSP-ERZS